Cargando…

Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

INTRODUCTION: Tertiary lymphoid structure expression and immune checkpoint inhibitors have been attracting attention, and their relationship with renal cell carcinoma is controversial. CASE PRESENTATION: Two patients with nivolumab plus ipilimumab treatment response for metastatic renal cell carcino...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sazuka, Tomokazu, Fujimoto, Ayumi, Sato, Hiroaki, Arai, Takayuki, Imamura, Yusuke, Sakamoto, Shinichi, Ikeda, Jun‐ichiro, Ichikawa, Tomohiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560443/ https://www.ncbi.nlm.nih.gov/pubmed/34755054 http://dx.doi.org/10.1002/iju5.12347

Ejemplares similares

A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
por: Sato, Hiroaki, et al.
Publicado: (2023)

Editorial Comment to Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
por: Yuasa, Takeshi
Publicado: (2021)

A case of ipsilateral three simultaneous renal cell carcinomas with different histologic types
por: Tanaka, Satoki, et al.
Publicado: (2023)

A case of bladder cancer after bilateral lung transplantation following bone marrow transplantation
por: Arai, Yutaro, et al.
Publicado: (2023)

Successful treatment of metastatic bladder cancer by gemcitabine‐cisplatin re‐challenge after pembrolizumab
por: Arai, Takayuki, et al.
Publicado: (2021)

Tumor localization by Prostate Imaging and Reporting and Data System (PI-RADS) version 2.1 predicts prognosis of prostate cancer after radical prostatectomy
por: Fujimoto, Ayumi, et al.
Publicado: (2023)

Relationship between Preoperative Pyuria and Bacille Calmette-Guerin Treatment in Intravesical Recurrence after Transurethral Resection of High-Risk, Non-Muscle Invasive, Bladder Carcinoma: A Retrospective Study of Human Data
por: Tsukamoto, Ryo, et al.
Publicado: (2023)

Deliberation on Deferred Cytoreductive Nephrectomy and Postoperative Treatment for Advanced Renal Cell Carcinoma: A Case Report
por: Nakagawa, Takuya, et al.
Publicado: (2022)

Tumor Location and a Tumor Volume over 2.8 cc Predict the Prognosis for Japanese Localized Prostate Cancer
por: Baba, Haruki, et al.
Publicado: (2022)

Left ileal conduit: A case report
por: Nakamura, Kazuyoshi, et al.
Publicado: (2019)

Contribution of the L-Type Amino Acid Transporter Family in the Diagnosis and Treatment of Prostate Cancer
por: Zhao, Xue, et al.
Publicado: (2023)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel
por: Ando, Keisuke, et al.
Publicado: (2021)

Cushing's syndrome in pregnancy in which laparoscopic adrenalectomy was safely performed by a retroperitoneal approach
por: Takeuchi, Nobuyoshi, et al.
Publicado: (2023)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
por: Fransen van de Putte, Elisabeth E., et al.
Publicado: (2023)

Cytoreductive Nephrectomy in 2021: Obsolete
por: Meza, Luis, et al.
Publicado: (2021)

New Paradigms for Cytoreductive Nephrectomy
por: Lichtbroun, Benjamin J., et al.
Publicado: (2022)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
por: Minervini, Andrea, et al.
Publicado: (2019)

Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: a systematic review and meta-analysis
por: Li, Kun-peng, et al.
Publicado: (2023)

Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer
por: Russo, Paul, et al.
Publicado: (2007)

Cytoreductive nephrectomy in the current treatment algorithm
por: Kuusk, Teele, et al.
Publicado: (2019)

Cytoreductive Nephrectomy in 2021: Obsolete but Necessary
por: Capitanio, Umberto, et al.
Publicado: (2021)

Cytoreductive Nephrectomy: Still Necessary in 2021
por: Méjean, Arnaud, et al.
Publicado: (2022)

Editorial Comment: Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial
por: Bex, A, et al.
Publicado: (2020)

Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients
por: Kanesaka, Manato, et al.
Publicado: (2021)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy
por: Sazuka, Tomokazu, et al.
Publicado: (2015)

A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy
por: Yonese, Ichiro, et al.
Publicado: (2020)

Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy
por: Leone, Andrew, et al.
Publicado: (2016)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Ipilimumab/nivolumab/tozinameran: Various toxicities: case report
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3jc3ihraoj2g71cl0nk3h3mhto